secwatch.observer — SEC 8-K summary
======================================

Issuer:     BAXTER INTERNATIONAL INC (BAX)
CIK:        0000010456
Form:       8-K
Filed at:   2024-02-08T23:59:59+00:00
Accession:  0001628280-24-003784
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Baxter Q4 sales $3.89B (+4%); full-year adj. EPS $2.60
------------------------------------------------------

- Q4 sales from continuing ops $3.89B (+4% reported, +3% constant currency); GAAP EPS $0.14, adjusted EPS $0.88.
- Full-year 2023 sales $14.81B (+2% reported, +3% constant currency); GAAP diluted loss ($0.15), adjusted EPS $2.60.
- Company progressed on new operating model, sale of BioPharma Solutions, and planned Kidney Care separation.
- CEO cited building momentum and improving macroeconomic/supply chain environment in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/10456/000162828024003784/0001628280-24-003784-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/10456/000162828024003784/bax-20240208.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-003784

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer